Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis
Summary
New approaches are needed to achieve more rapid elimination of dormant mycobacteria and thereby shorten treatment for drug-sensitive and drug-resistant tuberculosis (TB). Dormant mycobacteria are relatively resistant to antibacterial drugs and approaches that enhance immune clearance have the potential to be more effective. Interleukin-4 (IL-4) is a key cytokine in the immune response to TB that may impair the clearance of mycobacteria. We hypothesize that pascolizumab, an anti-IL-4 monoclonal antibody, might be of value as an adjunct to standard treatment. The aims of this trial are to determine whether administration of pascolizumab as an adjunct to standard combination treatment for drug-sensitive TB produces changes in one or more parameters of bacterial or host response (including bacterial clearance, host clinical status, immune response, bacterial and host transcriptomics, lung imaging) that may indicate potential for enhanced sterilization and to confirm the safety of blocking IL-4 (previously demonstrated in healthy volunteers and patients with asthma) in patients with TB.
Timeline
- Start
- 2012-06
- Primary completion
- 2017-02
- Completion
- 2017-07
Outcome
Mixed primary results
paper There were no study-drug-related G4/SAEs. PMID 38527849 ↗
paper Median week-8 TTP was 42 days in pascolizumab and placebo groups (P = .185). PMID 38527849 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pascolizumab | Monoclonal antibody | 0.05 mg/kg | Intravenous |
| Subject | Pascolizumab | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | Pascolizumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Pascolizumab | Monoclonal antibody | 10 mg/kg | Intravenous |